Active substanceMethyl ethylpyridinolMethyl ethylpyridinol
Similar drugsTo uncover
  • Cardiocipine
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Cardiocipine
    solution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Methyl ethylpyridinol
    solution for injections 
    ATOLL, LLC     Russia
  • Methyl ethylpyridinol
    solution for injections 
    ELLARA, LTD.     Russia
  • Methyl ethylpyridinol
    solution for injections 
    Company DEKO, LLC     Russia
  • Methyl ethylpyridinol-Eskom
    solution for injections 
    ESKOM NPK, OAO     Russia
  • Emoticon Optics
    drops d / eye 
  • Emoxibel
    solution d / infusion 
       
  • Emoxibel
    solution for injections 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Emoxibel
    drops d / eye 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Emoxibel
    solution w / m in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Emoxipine®
    drops d / eye 
  • Emoxipine
    solution w / m in / in 
  • Emoxipine
    drops d / eye 
    FARMENT FIRM, LLC     Russia
  • Emoxipine
    solution for injections 
  • Emoxipine-AKOS
    drops d / eye 
  • Emoxipine-Acti
    solution d / infusion 
    Aktifarm, OOO     Russia
  • Dosage form: & nbspinjection
    Composition:

    Per 1 ml:

    Active substance: methyl ethylpyridinol hydrochloride 10.0 mg;

    Excipients: 0.1 M hydrochloric acid solution to pH 2.5-3.5, water for injection up to 1.0 ml.

    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:Antioxidant
    ATX: & nbsp

    S.01.X.A   Other drugs for the treatment of eye diseases

    Pharmacodynamics:

    Methyl ethylpyridinol is an inhibitor of free radical processes and an antioxidant.

    Influences the blood coagulation system: reduces blood viscosity, inhibits platelet aggregation, reduces the overall coagulation index, prolongs the coagulation time. Stabilizes the membranes of cells of blood vessels and erythrocytes, increases the resistance of red blood cells to mechanical trauma and hemolysis. Reduces the permeability of the vascular wall, increases the content of cyclic nucleotides in platelets (cyclic adenosine monophosphate and cyclic guanosine monophosphate), has fibrinolytic activity, reduces the risk of developing hemorrhages, contributes to their resorption.

    Has retinoprotective properties,protects the eye from the damaging effect of high-intensity light, promotes resorption of intraocular hemorrhages, improves microcirculation in the tissues of the eye.

    Pharmacokinetics:The volume of distribution is 5.2 liters. The half-life is 18 min. The total ground clearance is 0.2 l / min. Metabolised in the liver. It is excreted by the kidneys.
    Indications:As part of complex therapy:
    • Subconjunctival and intraocular hemorrhages of various genesis;
    • Angioretinopathy (including diabetic);
    • Central and peripheral chorioretinal dystrophy;
    • Thrombosis of the central vein of the segment and its branches;
    • Complications of myopia;
    • Aigiosclerotic macular degeneration (dry form);
    • Detachment of the choroid in the postoperative period after surgery for glaucoma;
    • Dystrophic diseases of the cornea;
    • Injuries, corneal burns;
    • Treatment and prevention of eye lesions with high intensity light (sun rays, laser radiation during laser coagulation).
    Contraindications:Hypersensitivity to the active substance and / or any of the components of the drug, children under 18 years of age (efficacy and safety not established).
    Pregnancy and lactation:The use of the drug during pregnancy and during breastfeeding is allowed if the benefit to the mother exceeds the potential risk to the fetus and the baby.
    Dosing and Administration:

    The drug is used as part of complex therapy.

    With subconjunctival and intraocular hemorrhages of various origins subconjunctival or parabulbarno in 0.5 ml once a day. The course of treatment is 10-15 days.

    With angioretinopathy (including diabetic) - Parabulbarno on 0,5 ml once a day. The course of treatment is 10 days.

    With central and peripheral chorioretinal dystrophy, as well as angiosclerotic macular degeneration (dry form) - Parabulbar but 0.5 ml once a day. The course of treatment is 10-15 days.

    When thrombosis of the central vein of the retina and its branches - Parabulbar but 0.5 ml once a day. The course of treatment is 10-15 days.

    With complicated myopia - Parabulbarno on 0,5 ml once a day. The course of treatment - 10-30 days, it is possible to repeat the course 2-3 times a year.

    With detachment of the choroid in patients with glaucoma in the postoperative period - parabulbar or subconjunctival 0.5-1.0 ml once every 2 days. The course of treatment - 10 injections.

    With injuries and burns of the cornea 2 degrees - parabulbarno for 0.5 ml once a day. The course of treatment is 10-15 injections.

    With dystrophic diseases of the cornea - subconjunctival 0.5 ml once a day. The course of treatment is 10-30 days.

    For the protection of the retina in lacerocoagulation (including with limiting and destructive coagulation of tumors) - parabulbarno on 0,5-1,0 ml of 1% solution (5-10 mg) for 24 hours and for 1 hour before coagulation; then in the same doses (0.5 ml of 1% solution) once a day for 2-10 days.

    Side effects:

    Overdose may increase the severity of dose-dependent unwanted drug treatment.

    Symptoms: increased blood pressure, agitation or drowsiness, headache, pain in the heart, nausea, discomfort in the epigastric region. There may be a clotting disorder.

    Treatment: withdrawal of the drug, symptomatic therapy, there is no specific antidote.

    Interaction:Pharmaceutically it is not compatible with other medicinal products (it is forbidden to mix methyl ethylpyridinol in one syringe with other medicines).
    Special instructions:Treatment with methyl ethyl pyridinol should be carried out under the control of blood pressure and blood clotting.
    Effect on the ability to drive transp. cf. and fur:With the development of sleepiness, it is necessary to refrain from controlling vehicles and other moving mechanisms, as well as to be cautious in carrying out potentially dangerous activities requiring increased concentration of attention and speed of psychomotor reactions.
    Form release / dosage:Solution for injection 10 mg / ml.
    Packaging:

    1 ml per ampoule of colorless neutral glass type I with a colored break ring or with a colored dot and a notch or without a kink ring, a colored dot and a notch. One, two or three color rings and / or a two-dimensional bar code, and / or alphanumeric coding or without additional color rings, a two-dimensional bar code, and alphanumeric coding can additionally be applied to the ampoules.

    5 ampoules per circuit cell packaging made of polyvinylchloride film and aluminum foil foil or polymer film or without foil and without film. Or 5 ampoules are placed in a prefabricated form (tray) made of cardboard with cells for laying ampoules.

    1 or 2 contour squares or cardboard trays along with the instruction for use and a scarifier or knife with an ampoule,or without the scarifier and the ampoule knife are placed in a cardboard package (bundle).

    Storage conditions:In the dark place at a temperature of no higher than 25 ° C. Do not freeze. Keep out of the reach of children.
    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-003174
    Date of registration:07.09.2015
    Expiration Date:07.09.2020
    The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp08.05.2018
    Illustrated instructions
      Instructions
      Up